These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 2238667)

  • 1. Evaluation of effectiveness of mass screening for colorectal cancer.
    Fujita M; Sugiyama R; Kumanishi Y; Ota J; Horino T; Nakano Y; Taguchi T
    World J Surg; 1990; 14(5):648-52; discussion 652-3. PubMed ID: 2238667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood.
    Mandel JS; Church TR; Ederer F; Bond JH
    J Natl Cancer Inst; 1999 Mar; 91(5):434-7. PubMed ID: 10070942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparative study on the efficacy of a mass screening program for colorectal cancer--comparison between cancer cases detected by mass screening and by outpatient clinics.
    Nakama H
    Asia Pac J Public Health; 1994; 7(3):159-64. PubMed ID: 7794654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interval Colorectal Cancer Incidence Among Subjects Undergoing Multiple Rounds of Fecal Immunochemical Testing.
    van der Vlugt M; Grobbee EJ; Bossuyt PMM; Bos A; Bongers E; Spijker W; Kuipers EJ; Lansdorp-Vogelaar I; Spaander MCW; Dekker E
    Gastroenterology; 2017 Aug; 153(2):439-447.e2. PubMed ID: 28483499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mass screening for colorectal cancer in Japan.
    Hisamichi S; Fukao A; Fujii Y; Tsuji I; Komatsu S; Inawashiro H; Tsubono Y
    Cancer Detect Prev; 1991; 15(5):351-6. PubMed ID: 1751945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characteristics and survival rate of elderly patients with colorectal cancer detected by immunochemical occult blood screening.
    Zhang B; Fattah A; Nakama H
    Hepatogastroenterology; 2000; 47(32):414-8. PubMed ID: 10791202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study.
    Mandel JS; Bond JH; Church TR; Snover DC; Bradley GM; Schuman LM; Ederer F
    N Engl J Med; 1993 May; 328(19):1365-71. PubMed ID: 8474513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening for colorectal cancer with fecal occult blood testing and sigmoidoscopy.
    Winawer SJ; Flehinger BJ; Schottenfeld D; Miller DG
    J Natl Cancer Inst; 1993 Aug; 85(16):1311-8. PubMed ID: 8340943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Men with negative results of guaiac-based fecal occult blood test have higher prevalences of colorectal neoplasms than women with positive results.
    Brenner H; Hoffmeister M; Birkner B; Stock C
    Int J Cancer; 2014 Jun; 134(12):2927-34. PubMed ID: 24374771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival of patients diagnosed with colorectal cancer through a television-advertised screening program.
    Slusser SO; Liberski SM; McGarrity TJ
    Am J Gastroenterol; 1996 Aug; 91(8):1563-6. PubMed ID: 8759662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population colorectal cancer screening with fecal occult blood test.
    Rennert G; Rennert HS; Miron E; Peterburg Y
    Cancer Epidemiol Biomarkers Prev; 2001 Nov; 10(11):1165-8. PubMed ID: 11700264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes and cost evaluation of the first two rounds of a colorectal cancer screening program based on immunochemical fecal occult blood test in northern Italy.
    Parente F; Boemo C; Ardizzoia A; Costa M; Carzaniga P; Ilardo A; Moretti R; Cremaschini M; Parente EM; Pirola ME
    Endoscopy; 2013; 45(1):27-34. PubMed ID: 23254404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of a brush-sampling fecal immunochemical test for hemoglobin with a sensitive guaiac-based fecal occult blood test in detection of colorectal neoplasia.
    Smith A; Young GP; Cole SR; Bampton P
    Cancer; 2006 Nov; 107(9):2152-9. PubMed ID: 16998938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Features of colorectal cancer with fecal-occult-blood tests--comparison with colorectal cancer with no screening].
    Takemasa I; Kikkawa N; Yasui M; Nishisho I; Fujitani K; Mishima H; Hasuike Y; Kobayashi K
    Gan To Kagaku Ryoho; 1998 Aug; 25(10):1514-8. PubMed ID: 9725042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Screening for colorectal cancer: current status in Japan.
    Saito H
    Dis Colon Rectum; 2000 Oct; 43(10 Suppl):S78-84. PubMed ID: 11052482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interval cancers in a guaiac-based colorectal cancer screening programme: Consequences on sensitivity.
    Blom J; Törnberg S
    J Med Screen; 2017 Sep; 24(3):146-152. PubMed ID: 28142309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lower risk of advanced neoplasia among patients with a previous negative result from a fecal test for colorectal cancer.
    Denters MJ; Deutekom M; Bossuyt PM; Stroobants AK; Fockens P; Dekker E
    Gastroenterology; 2012 Mar; 142(3):497-504. PubMed ID: 22108194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The detection of colorectal cancer at an asymptomatic stage by screening is useful.
    Komuta K; Furui J; Haraguchi M; Kanematsu T
    Hepatogastroenterology; 2000; 47(34):1011-4. PubMed ID: 11020866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accuracy of immunological fecal occult blood testing for colorectal cancer screening.
    Nakama H; Kamijo N
    Prev Med; 1994 May; 23(3):309-13. PubMed ID: 8078851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fecal occult blood screening in the Minnesota study: sensitivity of the screening test.
    Church TR; Ederer F; Mandel JS
    J Natl Cancer Inst; 1997 Oct; 89(19):1440-8. PubMed ID: 9326913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.